Plasma apolipoprotein E levels and risk of dementia: A Mendelian randomization study of 106,562 individuals

[1]  S. Larsson,et al.  Alcohol Consumption and Cardiovascular Disease , 2020, Circulation. Genomic and precision medicine.

[2]  K. Langa,et al.  A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012 , 2017, JAMA internal medicine.

[3]  R. Frikke-Schmidt,et al.  Relation between plasma and brain lipids , 2016, Current opinion in lipidology.

[4]  A. Hofman,et al.  Serum apolipoprotein E is associated with long-term risk of Alzheimer’s disease: The Rotterdam Study , 2016, Neuroscience Letters.

[5]  B. Nordestgaard,et al.  Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population. , 2016, Atherosclerosis.

[6]  F. Alt,et al.  Long Neural Genes Harbor Recurrent DNA Break Clusters in Neural Stem/Progenitor Cells , 2016, Cell.

[7]  I. Weissman,et al.  A Mechanism for Somatic Brain Mosaicism , 2016, Cell.

[8]  B. Nordestgaard,et al.  Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease , 2015, Alzheimer's & Dementia.

[9]  B. Nordestgaard,et al.  HDL Cholesterol and Risk of Type 2 Diabetes: A Mendelian Randomization Study , 2015, Diabetes.

[10]  B. Nordestgaard,et al.  Plasma levels of apolipoprotein E and risk of dementia in the general population , 2015, Annals of neurology.

[11]  D. Holtzman,et al.  Apolipoprotein E levels and Alzheimer risk , 2015, Annals of neurology.

[12]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[13]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[14]  Peter Tontonoz,et al.  Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.

[15]  C. Wellington,et al.  High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. , 2014, Cell metabolism.

[16]  D. Holtzman,et al.  In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis , 2013, Molecular Neurodegeneration.

[17]  Sonia Shah,et al.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.

[18]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[19]  A. Fagan,et al.  Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. , 2012, Human molecular genetics.

[20]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[21]  D. Holtzman,et al.  Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.

[22]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[23]  C. Wellington,et al.  Why lipids are important for Alzheimer disease? , 2009, Molecular and Cellular Biochemistry.

[24]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[25]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[26]  S. Ebrahim,et al.  Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? , 2008, Human Genetics.

[27]  L. Kessing,et al.  Validity of Dementia Diagnoses in the Danish Hospital Registers , 2007, Dementia and Geriatric Cognitive Disorders.

[28]  Peter Tontonoz,et al.  Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors , 2007, Proceedings of the National Academy of Sciences.

[29]  M. Staufenbiel,et al.  Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* , 2005, Journal of Biological Chemistry.

[30]  D. Holtzman,et al.  Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[31]  M. Hayden,et al.  The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[32]  D. Holtzman,et al.  Differential metabolism of ApoE isoforms in plasma and CSF , 2003, Experimental Neurology.

[33]  B. Hyman,et al.  APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer’s disease diagnosis , 2003, Experimental Neurology.

[34]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[35]  P. de Knijff,et al.  ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels , 2000, Genetic epidemiology.

[36]  M. Bullido,et al.  Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene , 1998, FEBS letters.

[37]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[38]  S. Young,et al.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. , 1991, The Journal of clinical investigation.

[39]  R. Frants,et al.  Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels , 1988, Human Genetics.

[40]  Ninoslav Mimica,et al.  Dementia: a public health priority , 2019 .

[41]  M. Schumacher,et al.  Incidence of Dementia over Three Decades in the Framingham Heart Study. , 2016, The New England journal of medicine.

[42]  John X. Morris,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012 .

[43]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[44]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[45]  J. Danesh,et al.  Association of apolipoprotein E genotypes with lipid levels and coronary risk. , 2007, JAMA.

[46]  B. Hyman,et al.  APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. , 2003, Experimental neurology.

[47]  E. Boerwinkle,et al.  Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. , 1988, American journal of human genetics.